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Introduction
Human CD8 + cells expressing higher-than-average numbers of TCR (TCR hi ) reportedly have high functional avidity for their tumor targets (1) (2) (3) , as shown by their ability to lyse targets pulsed with smaller amounts of exogenous antigen (10 À7 to 10 À8 mol/L) than do CTLs expressing fewer TCR. These observations suggest that high TCR density compensates for the low affinity of individual TCRs for self-antigen. TCR hi CTLs, the most potent cytolytic effectors identified thus far, are scarce in patients with cancer (1) (2) (3) . In one study, some TCR hi cells were shown to be insensitive to antigen or died at antigen concentrations of 10
À6
mol/L (3); in another study, TCR hi cells expanded in response to antigen but required interleukin 7 (IL-7) and IL-10 for survival (2) . These findings suggest that tumor antigen transmitted a negative signal to block the differentiation of those CTLs and that the cytokines used for CTL expansion apparently amplified the negative signal. In ligand/receptor interactions, when the concentration of the ligand is constant, the effects of the ligand on the cell depend on the density of its receptor. At constant ligand concentration and constant receptor density, the functional effects of the ligand change with its affinity for the receptor or the duration of the receptor engagement.
To elucidate the significance of TCR density in the differentiation of TCR hi cells to cytolytic effectors, we modified the affinity of the ligand (antigen) for the receptor (TCR) and simultaneously analyzed the responses of two polyclonal CD8 + populations from the same individual that differed in the levels of TCR by one order of magnitude. Because the transition between mitosis and apoptosis in TCR hi cells responding to tumor antigen takes place within a narrow range of antigen concentrations (5 Â 10 À6 to 10 À7 mol/L; ref.
3), we modified the affinity of the antigen for TCR in the smallest possible changes (increments/decrements), using only atomic van der Waals forces from methylene (CH 2 ) groups appended to Gly. At only 2 kJ/mol (0.5 kcal/mol), van der Waals forces are the weakest forces between atoms; by comparison, the force involved in the formation of one hydrogen bond after the introduction of one hydroxyl group is 20 kJ/mol (4). Because longer and branched side chains produce steric hindrance and steric hindrance may offset gains from increments in van der Waals forces, we used only short linear CH 2 extensions. We used CTLs isolated from tumor-associated lymphocytes (TAL) that recognize an epitope from the HER-2/neu proto-oncogene, which is present on normal epithelial cells but is also overexpressed in many epithelial cancers of the breast, lung, prostate, and ovary (5). Because HER-2 is a self-antigen, most T cells of high affinity for HER-2 epitopes are deleted (6) , and the remainder cells recognize HER-2 peptides with low avidity (at about 10 À6 mol/L). Nevertheless, because the same HER-2 CTL epitopes are presented by substantial proportions of tumors, the CTL epitopes from HER-2 become significant for cancer therapy (7) . How undifferentiated TCR hi cells respond to human tumor antigen and what is needed to induce their proliferation and differentiation to functional effector cells remain unknown. To identify the optimal agonist for inducing differentiation of TCR hi cells, we constructed four variants of E75, the HER-2 (369-377) epitope for CTLs, by appending one, two, three, or four methylene groups to the glycine molecule at position 4 (Gly 4 ) to form a linear C side chain. We then selected cells expressing high concentrations of TCRs for E75 (E75-TCR hi ) to evaluate the role of TCR density in CTL differentiation upon stimulation with the same ligands. The TCR hi population which usually includes cells staining with antigen-tetramers/dimers with a mean fluorescence intensity (MFI) higher than 10 2 was divided in two populations, one staining with antigen-pulsed HLA-A2/IgG dimers (dimers) with a MFI (TCR) between 10 2 and 10 3 , and another which stained with antigen-pulsed dimers with a MFI (TCR) between 10 3 and 10 4 . These populations were designated as TCR med and TCR hi , respectively. The ability of CTLs to synthesize perforin is critical to their ability to lyse target cells (8, 9) . Presumably, cells with high-density TCR would need correspondingly high amounts of effector molecules such as perforin for maximum functionality. Perforin is undetectable in naive CTLs but is up-regulated in response to signals from TCRs (8) (9) (10) . Perforin also controls CD8 + homeostasis independently of its role as an effector molecule (11) (12) (13) . Large expansion of antigen-specific CD8 + cells that produce IFN-g in perforin-deficient mice resulted in lethal disease during viral infections (11, 14) . Most T cells with high affinity for selfantigen are deleted upon encountering that self-antigen. Deletion constitutes a mechanism for protection against autoimmunity (6, 15) . We sought to determine how to induce differentiation of such cells and to identify the factors controlling their differentiation and survival. The difficulty in addressing these questions is compounded in polyclonal human systems, not only because surviving TALs recognize antigen with low functional avidity because their perforin expression is impaired (16, 17) , but also because a large number of TCRs with distinct affinities for antigen are present. 
Materials and Methods
Cells, antibodies, and cytokines. The ovarian TAL line TAL-1 was generated from heparinized ovarian ascites, collected under institutionally approved protocols. Lymphocytes from TAL-1 were cultured in the presence of low concentrations of IL-2 (150-300 IU/mL) for 7 to 14 days. Stimulation of these TAL-1 cells with 200 to 1,000 nmol/L of any Gly 4 variant resulted in their secreting IFN-g at levels increasing in tandem with the length of the CH 2 chain, indicating that the E75-TCR + cells in the TAL-1 population were functional and not tolerized (data not shown). Monoclonal antibody (mAb) used for detecting surface antigen and cytokines used for culturing T cells from TAL-1 are described elsewhere (18) . APC-conjugated antibody to IFN-g (IgG2a), PE-conjugated mouse (IgG2b) antibody to perforin (yG9), empty recombinant soluble dimeric human HLA-A2/IgG1 designated as ''dimers, '' and all specific isotype immunoglobulin controls were obtained from BD PharMingen (San Diego, CA). Proteasome and caspase inhibitors were obtained from R&D Systems (Minneapolis, MN) .
Synthetic peptides. The peptides used were E75 (HER-2 [369-377], KIFGSLAFL; ref. 19 ) and its methylene-appended C side chain variants. Four CH 2 variants were generated by substituting the glycine at position 4 (Gly 4 ) with alanine and one of following synthetic amino acids: gaminobutyric acid, norvaline, or norleucine (Advanced Chemtech, Louisville, KY). The abbreviations for the CH 2 -extended E75 variants (G4.1, G4.2, G4.3, and G4.4) reflect the position (Gly 4 ) and number of the CH 2 group extensions (19) . Another variant in which the alanine at position 7 (Ala 7 ) was replaced with norleucine was designated A7.3. All peptides were prepared by Dr. Martin Campbell (Peptide Synthesis Core Facility of the University of Texas M.D. Anderson Cancer Center). Amino acids were coupled in sequential format from the COOH terminus using standard N-(9-fluorenyl)methoxycarbonyl peptide chemistry on a Rainin Symphony Automated Peptide Synthesizer and purified by high-performance liquid chromatography. The purity of the peptides ranged from 95% to 97%. Peptides were dissolved in PBS and stored at À20jC as aliquots of 2 mg/ mL until use. Molecular modeling of peptide/HLA-A2 complexes was done using as model the crystal structure of Tax peptide bound to HLA-A2 (18) .
T cell/peptide-HLA-A2 dimer association and dissociation assays. Expression of TCRs specific for HLA-A2 bound to the E75 peptide (E75-TCR + cells) was determined by using E75 dimers (dE75). dE75 were prepared as previously described (18) . Staining of cells was done as described previously (19) (20) (21) . Specific geometric (y . T-cell stimulation by the CH 2 variants. Apoptosis was induced in TAL-1 by two successive stimulations with 10,000 nmol/L of each peptide pulsed on T2 cells. Surviving TAL-1 were then primed with 5,000 nmol/L of each peptide pulsed on irradiated T2 cells as described elsewhere (24, 25) . Control cultures were stimulated with T2 cells that had been pulsed with peptide A7.3. The death-resistant cells were restimulated in vitro with irradiated T2 cells pulsed with each peptide at a final concentration of 5 Amol/L, expanded in IL-2 (150 IU/mL; C1/A1) and maintained over feeders. Expression of IFN-g and perforin, markers of differentiation, was determined by using IFN-g-APC-conjugated or perforin-PE-conjugated antibodies and matched PE/FITC/APC-conjugated isotype controls on dE75-stained and permeabilized cells (18) . Fold expansion by each variant was calculated by dividing the number of E75-TCR hi /TCR med cells detected in each sample after stimulation by the number of E75-TCR hi /TCR med cells present before stimulation.
CTL assays. E75-, A7.3-, and G4.1-to G4.4-stimulated TAL-1 were used as effectors in CTL assays. Antigen recognition by the E75 variantinduced CTLs was determined as described elsewhere (26, 27) . Recognition of E75 was considered specific when the mean specific lysis of T2 cells pulsed with E75 minus the SD was at least 10% and was at least twice as high as the percentage of specific lysis of T2 cells that had not been pulsed with peptide, plus the SD (27) E75-specific tumor lysis was determined by subtracting the levels of SKOV3.A2 tumor lysis CTL Differentiation by CH 2 -Appended Antigen www.aacrjournals.org observed in the presence of T2-E75 cells from the levels of SKOV3.A2 tumor lysis observed in the presence of T2-NP cells (27) . The tumor cells were then incubated with 10 Amol/L MG132 (28, 29) for 30 minutes, before and during labeling, and used as targets in CTL assays. High-and medium-avidity effector CTLs were distinguished in two ways: first, by their ability to recognize E75 at concentrations at least two times lower than the E75-primed CTL (e.g., at 500 nmol/L instead of at 1,000 nmol/L) and second by the ability of high-avidity CTLs to mediate an effector response (e.g., % specific lysis) that was (a) at least twice as high as the effector response at the same or lower antigen concentration and/or (b) at half the effector-to-target ratio of the medium-avidity CTLs (30) .
Caspase inhibitors. The caspase inhibitors Z-IETD-fluoromethyl ketone-( fmk) (specific for caspase-8), Z-LEHD-fmk (specific for caspase-9), and EDVE-fmk (specific for caspase-3), have been reported to participate in perforin-mediated apoptosis (31) . For these experiments, 2 Â 10 6 G4.2-induced CTL were incubated with each caspase inhibitor at 37jC for 90 minutes, washed twice with PBS, and stimulated with T2 cells pulsed with 5 Amol/L of G4.2.
Statistical analysis. Differences in the levels of IFN-g, perforin, and cytolysis between groups were compared by using unpaired Student's t tests from triplicate determinations. Differences were considered significant at P < 0.05.
Results
Extending peptide side chains with CH 2 modifies the affinity of E75 for TCR. Molecular modeling of the E75-HLA-A2 complex indicated that CH 2 extension in Gly 4 resulted in zigzag orientation of the CH 2 chain towards the solvent (Fig. 1A , B, C, and D). Peptide/HLA-A2 association and dissociation assays indicated that appending CH 2 groups did not increase the affinity of the variants for HLA-A2 over that for E75 and the stability of peptide/HLA-A2 complexes. In brief, the MFI for HLA-A2, on T2 cells incubated with peptides overnight, followed by staining with BB7.2 mAb, were E75 = 151, G4.2 = 142, and G4.4 = 137 (data not shown). Peptide-HLA-A2 IgG dimer/TAL-1 association and dissociation assays, done to determine how the CH 2 appendages affected the affinity of the peptide-HLA-A2 complex for TCR, showed that at t 0 , TAL-1 stained more strongly with dG4.2, dG4.3, or dG4.4 than with dE75 or dG4.1, meaning the ligands G4.2, G4.3, and G4.4 had higher affinity for TCR (Fig. 1E) . dG4.1 staining was weaker than dE75 staining. G4.1 dissociated faster than E75, G4.2 dissociated slightly slower than E75, whereas G4.3 and G4.4 dissociated slower than G4.2. The overall specific affinity for TCR of each variant increased with addition of CH 2 groups but showed saturation at G4.4 (Fig. 1E) . Changes in the MFI confirmed that each CH 2 group in the G4.1 to G4.4 variants interacted with the TCR; moreover, each CH 2 group added to the chain affected the interaction of the existing CH 2 groups with the TCR and changed the affinity of the other groups for TCR and the stability of the TCR/peptide HLA-A2 complexes (Fig. 1E) . Results in Fig. 1F show the average change in MFI (TCR hi ) and MFI (TCR med ) per added CH 2 group at t 0 (0 hour) and 2 hours later. Both MFI (TCR hi ) and MFI (TCR med ) formed bell-shaped plots which peaked with G4.3 and G4.2, respectively. These results indicate that affinity of variants for TCR increased only within a range. In summary, except for the single-methylene-group variant G4.1, CH 2 extension increased the binding affinity of the variant for TCR hi without increasing the binding affinity for HLA-A2. Priming Fig. 2A) and most of the IFN-g + cells (also appendices). A7.3, the CH 2 position control peptide for G4.4, also induced deletion of TCR hi Perf + cells (Fig. 2A) Fig. 2B and C indicate that CH 2 appendage was effective in inducing differentiation of both TCR hi and TCR med cells, but the effects differed, depending on the position of the appendage (G4 or A7) and the density of the TCR. We quantitated the effects of stimulation with variants of polyclonal populations only on the cells expressing E75-TCR. The effects of the variants on cells expressing specific TCR for the variants, or reacting with the variants with higher affinity than with E75 have not been determined. Therefore, it may not be excluded that cells (e.g., E75-TCR med ) are also G4.2-TCR hi cells. The patterns of specific MFI (TCR) for variants-dimer complexes show parallels (Fig. 1F) with the E75-TCR med Perf + cells (Fig. 2C) . To identify the effects of restimulation in E75-TCR + cell differentiation, all cultures were restimulated with T2 cells pulsed with the same amounts of priming peptide, as in vaccination studies. Results in Fig. 2D show a significantly higher increase in the numbers of E75-TCR hi cells in cultures stimulated with G4.1, G4.2, and G4.4 compared with E75-TCR med cells in the same cultures. E75-TCR hi cells increased by 6-and 7-fold, respectively, in cultures restimulated by G4.1 and G4.4 and by >20-fold in cultures stimulated by G4.2. E75-TCR hi cells stimulated by E75 and G4.3 increased less in numbers and became apoptotic. E75-TCR med cells expanded less at restimulation with E75, G4.1, and G4.2 (3-, 4-, and 5-fold, respectively) but did not expand at restimulation with G4.3 and G4.4. Because these populations are polyclonal, we cannot distinguish whether expansion of TCR hi cells was due to a higher rate of division of only TCR hi cells or to a 3-to 4-fold increase in the numbers of E75-TCR molecules per cell in populations of E75-TCR med cells, or both. The increase in E75-TCR hi cells in cells stimulated with G4.1, of lower affinity for TCR than E75, is surprising and suggests a process similar with homeostatic proliferation and differentiation induced by low affinity ligands.
Perforin expression has been associated with terminal differentiation of CTL and their effector function (32) (33) (34) . To address whether E75-TCR + cell expansion affected their state of differentiation, we determined the levels of expression of perforin in these cells. Results in Fig. 3A show that E75-TCR hi cells which lacked perforin after priming, expressed high levels of perforin after restimulation. Representative histograms (G4.2 restimulated) are shown in Supplemental Material. In contrast, E75-TCR med cells which expressed higher levels of perforin at priming, expressed reduced levels of perforin at restimulation. Because both E75-TCR hi and E75-TCR med cells were present in the same culture, were stimulated in the same conditions, and were stained in the same tube, the results indicate that E75-TCR med cells expressing higher levels of perforin were deleted at restimulation. Contraction of the Perf + population may account for weaker expansion of TCR med cells restimulated with G4.1 and G4.2 and for lack of expansion of TCR med cells restimulated with G4.3 and G4.4. Figure 3A also shows that E75-TCR hi cells expressed three to four times higher levels of perforin than restimulated E75-TCR med cells. E75-TCR hi cells restimulated with G4.1, G4.2, and G4.4 expressed higher levels of perforin than E75-TCR hi cells restimulated by G4.3. We cannot exclude the possibility that some of the E75-TCR med cells increased both the number of TCR molecules per cell and the amount of perforin per cell and become E75-TCR hi cells.
CTLs induced with G4.2 lyse tumor cells. To address whether variant activated CTL had higher functional avidity for E75 than E75-activated CTL, we assessed the recognition of E75 by variantinduced CTLs. In the first experiment (Fig. 3B ), effectors were variant-primed cells, and only the TCR med populations expressed perforin. In the brief (4-hour assay), only G4.4-CTLs significantly recognized E75 (>10% lysis) at concentrations of 100 and 500 nmol/L, whereas lysis by G4.2 CTL was below the 10% cutoff level to be considered significant. The levels of perforin were slightly higher in E75-TCR med cells stimulated with G4.2 and G4.4 than in E75-TCR med cells stimulated with G4.1 and G4.3 (Fig. 3A) . The levels of IFN-g (G4.2: MFI (IFN-g) = 25.9, G4.4 MFI (IFN-g) = 18.23) , and E75-TCR (G4.2: MFI (y 2 ) = 212, G4.4 MFI (y 2 ) = 158) were similar in G4.2 and G4.4 primed cells. Thus, the results suggest a better ''fit'' between E75 presented by the target and the TCR med of CTL primed by G4.4 than the TCR med primed by G4.2, or G4.3. E75-CTL did not recognize E75 at this concentration, but rather required 2,500 nmol/L of the peptide for lysis to be detected (data not shown). In the extended (22 hours) CTL assay, variant-induced CTLs mediated similar levels of lysis of T2-E75 (additional data in the appendix). This suggested that the affinity of TCR for the ligand and the TCR-peptide-MHC conformational fit and not the small differences in perforin expression determined the effectiveness of these CTL.
To determine whether expression of perforin in E75-TCR hi cells increased the functional avidity of the effectors, we repeated the assays with variant-restimulated cells at a lower E/T ratio (1:2). (Fig. 3C ) We found that G4.2-CTL recognized E75 at a concentration of 50 to 100 nmol/L. The functional avidity of G4.2-CTL for E75 was increased by a factor of at least four at restimulation ( from 7% lysis at 1:1 ratio to 19.5% lysis at 1:2 ratio); the functional avidity of G4.4-CTL increased by a factor of two ( from 15% lysis at 1:1 ratio to 20% lysis at 1:2 ratio), whereas the functional avidity of G4.1 cells increased by a factor of 10 from (3% lysis at 1:1 ratio to 16% lysis at 1:2 ratio). Therefore, G4.2-expanded TCR hi Perf + cells of higher functional avidity for E75 than G4.4 and G4.1. The higher functional avidity was a factor of both perforin levels and of the better ''fit'' TCR-peptide MHC interaction.
G4.3-reactivated and G4.1 reactivated cells died in large numbers and this resulted in elimination of CTL which recognized E75 with high affinity. Specific lysis by G4.1 stimulated CTL for 500 nmol/L E75 decreased to 6% in a second experiment (data not shown). The levels of perforin were similar in G4.1 and G4.4 reactivated cells and higher in G4.2-reactivated cells than in G4.3-reactivated cells. G4.2-expanded more CTL of higher functional avidity for E75 which survived longer than CTL stimulated with E75, G4.1, and G4.3.
To determine whether the higher functional avidity for E75 reflected a high functional avidity for tumor, we assessed E75-specific tumor lysis in E75-blocking experiments. In these experiments, SKOV3.A2 cells were treated or not treated with IFN-g to activate antigen presentation. IFN-g treatment increased the levels of HLA-A2 by a factor of three, as indicated by an increase in MFI for HLA-A2 from 114 to 342 (data not shown). To verify that E75 was being processed endogenously, we treated targets with the proteasome inhibitor MG132 before adding the effectors. The IFN-g-treated SKOV3.A2 cells were more sensitive to G4.2-CTL in the 4-hour CTL assay than were the untreated SKOV3.A2 cells (Fig.  3D) . Lysis of IFN-g-treated tumor cells by G4.2-CTL had continued to increase at 20 hours, demonstrating that G4.2-CTL had high and stable functional avidity for E75. MG132 inhibited SKOV3.A2 lysis by 60% in the 4-hour CTL assay (Fig. 3D) , indicating that most of the E75 was being processed by proteasomes.
Activation by G4.2 in the presence of caspase-9 inhibitor increases the numbers of TCR hi Perf hi cells. Induction of TCR hi Perf + cells raised the question of whether these cells were sensitive to antigen-induced apoptosis and, if so, how to avoid antigen-induced cell death. To identify the pathway of preferential deletion by antigen of Perf + cells, expressing high levels of perforin, the G4.2 cells used in the previous experiment were ''rested'' by culturing them in the absence of IL-2, treated with an inhibitor of caspase-8 or caspase-9, or remained untreated, and then stimulated with G4.2. IL-2 was added 24 hours later to avoid interference with TCR stimulation. Perforin expression was measured 48 hours later in E75-TCR hi Perf + cells, and as an internal control in E75-TCR med Perf + cells. Although separation of these cells at MFI (10 3 ) is arbitrary, from the levels of perforin, two populations were clearly distinguished in both TCR hi and TCR med cells: one population expressing MFI (Perf) <100 and a second population expressing MFI (Perf) >300.
Pretreatment with the caspase-8 inhibitor increased the number of E75-TCR hi cells by only 15% and decreased their perforin level by 10% compared with cells stimulated with G4.2 in the absence of caspase-8 inhibitor. (Fig. 4A versus B) . By contrast, treating the G4.2 cells with the caspase-9 inhibitor doubled the number of TCR hi cells and produced a 50% increase in MFI (perforin) relative to stimulation with only G4.2 ( Fig. 4C versus A) . These findings indicate that G4.2 induced death in TCR hi Perf hi cells by activating caspase-9. In contrast, in E75-TCR med cells, the caspase-8 inhibitor was more protective than the caspase-9 inhibitor, increasing the numbers of E75-TCR med cells by 62% (Fig. 4E ) as opposed to only 23% for the caspase-9 inhibitor (Fig. 4F) relative to the cells, which were not pretreated with caspase-inhibitor (Fig. 4D) . However, the levels of perforin, in the Perf hi population, increased by 21% in the caspase-9 inhibitor-treated population, suggesting that caspase-9 is activated by TCR to delete cells expressing high levels of perforin.
Discussion
CD8
+ cells expressing large numbers of TCR are important for immunotherapy because they can recognize the small amounts of endogenous antigen presented by tumors (1-3). We report here several novel findings regarding the fine tuning of the affinity of the antigen in the differentiation of TCR hi cells to high-functionalavidity, perforin-expressing cells.
These findings were obtained by simultaneous analysis of two human T-cell populations expressing a specific TCR for the same antigen that differed in the amount of TCR expressed per cell by one order of magnitude. The ''classic'' TCR hi population (of MFI >10 Expansion in TCR hi cells was not associated with affinity of the antigen for TCR or with the stability of peptide-MHC/TCR complexes, as would be expected in classic models of TCR signaling. Responses at priming were weak and they increased at restimulation with G4.2, the agonist of intermediate affinity for TCR inducing stronger expansion than G4.3 and G4.4. Expansion, perforin and IFN-g induction in the TCR med cells paralleled the changes in affinity of the ligand for TCR for G4.2, G4.3, and G4.4. Based on functional assays, G4.2 seemed the most effective among the CH 2 variants. G4.2-reactivated cells recognized antigen at lower concentrations than G4.4-and G4.1-reactivated cells.
The differences in ligand-receptor (TCR) affinity reflected differences in atomic forces induced in the CH 2 chain by the addition of single CH 2 groups. The average affinity for TCR per CH 2 group appended was lower in G4.2 than in G4.4 at t 0 and was higher in the G4.3 variant than in the G4.2 or G4.4 variants. The fact that this difference corresponds to van der Waals forces of only 0.5 to 1 kcal/ mol indicates the extraordinary sensitivity of TCR hi and TCR med cells to forces that are a full order of magnitude weaker than the forces generated by one hydroxyl group (5 kcal/mol). Unexpectedly, optimal affinity in these experiments corresponded to the linear extension of the side chain of E75 with two CH 2 groups, a variant not present in natural amino acids.
Our results indicate that expansion of TCR hi Perf hi cells of high functional avidity for tumor antigen require fine-tuning of the antigen affinity for the TCR to the best ''fit'' of TCR which activate the survival and lytic programs. In support of these conclusions, mutations in the side chains of some amino acids of HLA-A2 inhibited recognition of epitopes by specific CTL. This seemed the result of conformational changes in the peptide HLA-A2 (35) . Conformational changes at the TCR-peptide-HLA-A2 interface after initial binding seem to be essential for recognition of antigen by CTL (36) . We cannot address at this time, whether small differences in perforin levels in effectors (e.g., G4.1-CTL versus G4.3-CTL) resulted in differences in the observed tumor lysis. Because expression of high levels of perforin in CTLs is followed by apoptosis when the TCR is restimulated by the ligand, approaches to protect, partially differentiated and differentiated CTL, such as the ones induced by G4.1 and G4.3, using caspase inhibitors, will ultimately result in higher numbers of effector TCR hi Perf + cells than reactivation with wild-type agonists.
Our results suggest that changes in ligand affinity by substitutions with natural amino acids will be unable to modulate the weak forces executing differential control of effector gene expression in TCR hi cells. Differences of only two methylene groups (e.g., Gly versus g-aminobutyric acid) are absent in natural amino acids; in addition, differences of one CH 2 group in linear chains of three to four CH 2 groups are not present in natural amino acids. The side chains of Val and Leu/Ile differ in one amino acid length and are branched. Differences in van der Waals forces from one CH 2 group in Ser and Thr should be masked by the 10-fold stronger forces from -OH groups. Synthetic amino acids are not genetically encoded; although some are generated in humans by enzymatic reactions during metabolism (e.g. g-aminobutyric acid, a neurotransmitter), they are not known to be incorporated into proteins. Expression of synthetic amino acids in proteins suggests that posttranslational modifications, such as methylation/ demethylation of a CTL epitope, may be taking place if the corresponding bacterial enzymes are present (37) . The presence of norvaline and norleucine in bacterial proteins, in recombinant proteins, and in antibiotics, raises the possibility that TCR hi cells specific for self-antigen are periodically activated and inactivated after interactions with bacterial or fungal pathogens.
In summary, our results provide a novel basis for possible control of proliferation and terminal differentiation of human antitumor CTLs that recognize self-antigen. The sensitivity to small changes in atomic force shown by different responses to a one to two CH 2 difference in the antigen may be useful in the induction of antitumor responses. 
